Literature DB >> 9554431

Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics.

J H Krystal1, I L Petrakis, E Webb, N L Cooney, L P Karper, S Namanworth, P Stetson, L A Trevisan, D S Charney.   

Abstract

BACKGROUND: This study evaluated the dose-related ethanol-like subjective effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine hydrochloride in recently detoxified alcoholics.
METHODS: Twenty male inpatients meeting DSM-III-R criteria for alcohol dependence and who had not consumed alcohol for 10 to 27 days prior to the study completed 3 test days that involved the intravenous infusion of ketamine hydrochloride (0.1 mg/kg or 0.5 mg/kg) or saline solution under randomized double-blind conditions. Ethanol-like subjective effects were assessed using the Sensation Scale; the Biphasic Alcohol Effects Scale; visual analog scales to measure "high" and degree of similarity to ethanol, cocaine, and marijuana; a scale assessing the number of standard alcohol drinks producing similar subjective effects; and visual analog scales measuring ethanol craving.
RESULTS: Ketamine produced dose-related ethanol-like effects on each scale measuring its similarity to ethanol. Its effects were more similar to the sedative or descending limb effects of ethanol than to the stimulant or ascending limb effects. Ketamine effects also were more like ethanol than marijuana or cocaine. Ethanol-like effects were more prominent at the higher ketamine dose, a dose rated as similar to greater levels of ethanol intoxication. However, ketamine did not increase craving for ethanol.
CONCLUSION: The production of ethanol-like subjective effects by ketamine supports the potential clinical importance of NMDA receptor antagonism among the mechanisms underlying the subjective effects of ethanol in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554431     DOI: 10.1001/archpsyc.55.4.354

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  51 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Interactions among positions in the third and fourth membrane-associated domains at the intersubunit interface of the N-methyl-D-aspartate receptor forming sites of alcohol action.

Authors:  Hong Ren; Yulin Zhao; Donard S Dwyer; Robert W Peoples
Journal:  J Biol Chem       Date:  2012-06-19       Impact factor: 5.157

3.  Ketamine - A Multifaceted Drug.

Authors:  Lingzhong Meng; Jian Li; Yi Lu; Dajin Sun; Yuan-Xiang Tao; Renyu Liu; Jin Jun Luo
Journal:  Transl Perioper Pain Med       Date:  2015

Review 4.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

Review 5.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

Review 6.  Serotonergic dysfunction: brain imaging and behavioral correlates.

Authors:  Jana Wrase; Matthias Reimold; Imke Puls; Thorsten Kienast; Andreas Heinz
Journal:  Cogn Affect Behav Neurosci       Date:  2006-03       Impact factor: 3.282

7.  Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal-induced seizures and delirium tremens.

Authors:  Andre Tadic; Norbert Dahmen; Armin Szegedi; Dan Rujescu; Ina Giegling; Gabriele Koller; Ion Anghelescu; Christoph Fehr; Christoph Klawe; Ullrich W Preuss; Thomas Sander; Mohammad R Toliat; Peter Singer; Brigitta Bondy; Michael Soyka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

8.  D-amino acid aberrations in cerebrospinal fluid and plasma of smokers.

Authors:  Jurjen J Luykx; Steven C Bakker; Loes van Boxmeer; Christiaan H Vinkers; Hanne E Smeenk; Wouter F Visser; Nanda M Verhoeven-Duif; Eric Strengman; Jacobine E Buizer-Voskamp; Lizzy de Groene; Eric Pa van Dongen; Paul Borgdorff; Peter Bruins; Tom J de Koning; René S Kahn; Roel A Ophoff
Journal:  Neuropsychopharmacology       Date:  2013-04-24       Impact factor: 7.853

Review 9.  How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective.

Authors:  Peter Clapp; Sanjiv V Bhave; Paula L Hoffman
Journal:  Alcohol Res Health       Date:  2008

10.  Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

Authors:  Sanjay J Mathew; James W Murrough; Marije aan het Rot; Katherine A Collins; David L Reich; Dennis S Charney
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-17       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.